Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Regen BioPharma Inc

Get SEC filing alerts via email and in your feed for Regen BioPharma Inc

RGBP RGBPP

Regen BioPharma Inc

About Regen BioPharma Inc

Regen Biopharma, Inc. develops regenerative and immunotherapy treatments, focusing on cellular therapies, gene silencing, and immune modulation. Its core products include HemaXellerate for bone marrow repair and various cancer immunotherapies targeting NR2F6. The company licenses its innovative biotech IP, collaborates with partners, and advances preclinical and clinical research to develop novel biologics for rare diseases and cancer.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Regen BioPharma Inc

1
1
Regen BioPharma Inc Regen BioPharma Reports Stable Revenue but Increased Operating Losses and Significant Net Income Turnaround

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Regen BioPharma Inc Regen BioPharma Reports Stable Revenue but Increased Losses and Operating Expenses for December 2025 Quarter

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Regen BioPharma Inc Regen BioPharma Reports Fiscal Year 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 5 months ago | 0 comments

4
1
Regen BioPharma Inc Regen BioPharma Reports $59.1M Revenue for Q3 2025, Sees Significant Operating Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Regen BioPharma Inc Regen BioPharma Reports Stable Revenue but Increased Net Loss for Q2 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Regen BioPharma Inc Regen BioPharma Reports Financial Results for Quarter Ending December 31, 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Regen BioPharma Inc Regen BioPharma Reports Stable Revenue but Significant Losses for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments